Unjha Formul.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE576D01015
NSEID:
BSEID: 531762
View on BSE

INR

19.20

-0.75 (-3.76%)

BSENSE

Jun 10, 03:30 PM

BSE+NSE Vol: 891

{
  "main_header": {
    "sid": 782664,
    "name": "Unjha Formul.",
    "stock_name": "Unjha Formul.",
    "full_name": "Unjha Formulations Ltd",
    "name_url": "stocks-analysis/unjha-formul",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "19.20",
    "chg": -0.75,
    "chgp": "-3.76%",
    "dir": -1,
    "prev_price": "19.95",
    "mcapval": "9.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531762,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE576D01015",
    "curr_date": "Jun 10, 03:30 PM",
    "curr_time": "04:54 AM",
    "last_traded_at": "Jun 10, 03:30 PM IST",
    "bse_nse_vol": "891 ",
    "exc_status": "Active",
    "traded_date": "Jun 10, 2026",
    "traded_date_str": "2026 06 10",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/unjha-formul-782664-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Unjha Formulations Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-ltd-downgraded-to-strong-sell-amid-weak-financials-and-bearish-technicals-4030081",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/UnjhaFormulatio_mojoScore_4030081.png",
        "date": "2026-06-02 08:28:41",
        "description": "Unjha Formulations Ltd has been downgraded from a Sell to a Strong Sell rating as of 1 June 2026, reflecting deteriorating technical indicators and persistent financial weaknesses. Despite a very attractive valuation, the company’s flat quarterly performance, operating losses, and bearish technical trends have compelled analysts to revise their outlook, signalling caution for investors in this pharmaceuticals micro-cap."
      },
      {
        "title": "Unjha Formulations Ltd Upgraded to Sell on Technical Improvements Despite Financial Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-ltd-upgraded-to-sell-on-technical-improvements-despite-financial-challenges-4012896",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/UnjhaFormulatio_mojoScore_4012896.png",
        "date": "2026-05-26 08:20:17",
        "description": "Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 25 May 2026, driven primarily by a shift in technical indicators despite ongoing challenges in financial performance and valuation metrics. This nuanced change reflects a complex interplay of quality, valuation, financial trends, and technical signals that investors should carefully consider."
      },
      {
        "title": "Are Unjha Formulations Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-unjha-formulations-ltd-latest-results-good-or-bad-3999521",
        "imagepath": "",
        "date": "2026-05-19 19:17:21",
        "description": "Unjha Formulations Ltd's Q4 FY26 results highlight a complex operational landscape characterized by significant revenue growth juxtaposed with widening losses. The company reported net sales of ₹3.28 crores for the quarter, reflecting a year-on-year increase of 38.40% from ₹2.37 crores in Q4 FY25. However, this revenue growth did not translate into profitability, as the company experienced a net loss of ₹0.74 crores, which is a deterioration from the loss of ₹0.41 crores in the same quarter last year.\n\nThe quarter-on-quarter performance reveals further challenges, with a notable decline in revenue of 25.62% from ₹4.41 crores in Q3 FY26. This decline coincided with a shift from a profit of ₹0.24 crores in the previous quarter to a loss of ₹0.74 crores, raising concerns about the company's operational stability.\n\nOperating margins also reflected significant strain, with an operating margin of -13.72% in Q4 FY..."
      },
      {
        "title": "Unjha Formulations Q4 FY26: Losses Deepen Despite Revenue Growth as Operational Challenges Mount",
        "link": "https://www.marketsmojo.com/news/result-analysis/unjha-formulations-q4-fy26-losses-deepen-despite-revenue-growth-as-operational-challenges-mount-3997539",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/UnjhaFormulatio_quaterlyResult_3997539.png",
        "date": "2026-05-18 20:46:31",
        "description": "Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported a troubling quarterly performance for Q4 FY26, posting a net loss of ₹0.74 crores despite revenue growth. The micro-cap company, with a market capitalisation of ₹9.00 crores, saw its stock decline 0.55% to ₹20.00 following the results announcement, reflecting investor concerns about deteriorating profitability and operational challenges that have plagued the company throughout the fiscal year."
      },
      {
        "title": "Unjha Formulations Ltd Downgraded to Strong Sell Amid Technical and Financial Weakness",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-ltd-downgraded-to-strong-sell-amid-technical-and-financial-weakness-3980901",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/UnjhaFormulatio_mojoScore_3980901.png",
        "date": "2026-05-08 08:05:33",
        "description": "Unjha Formulations Ltd has been downgraded from a Sell to a Strong Sell rating as of 7 May 2026, reflecting deteriorating technical indicators and underwhelming financial performance. The company’s micro-cap status, combined with a sharp decline in share price and weak debt servicing ability, has prompted a reassessment of its investment appeal across quality, valuation, financial trend, and technical parameters."
      },
      {
        "title": "Unjha Formulations Ltd Upgraded to Sell on Technical Improvement Despite Mixed Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-ltd-upgraded-to-sell-on-technical-improvement-despite-mixed-fundamentals-3969563",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/UnjhaFormulatio_mojoScore_3969563.png",
        "date": "2026-04-30 08:03:55",
        "description": "Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 April 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The micro-cap pharmaceutical company’s Mojo Score has improved to 31.0, reflecting a nuanced change in market sentiment and technical trends, even as financial performance remains flat and long-term fundamentals show weaknesses."
      },
      {
        "title": "Why is Unjha Formulations Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-unjha-formulations-ltd-fallingrising-3969264",
        "imagepath": "",
        "date": "2026-04-30 01:38:25",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Intraday Volatility and Trading Dynamics</strong></p>\n<p>Despite opening the day with a gap down of 6.47%, the stock managed to recover strongly, touching an intraday high of ₹22.00. The trading range was wide, spanning ₹2.5, reflecting significant price fluctuations throughout the session. The weighted average price indicated that a larger volume of shares was traded closer to the day’s low, suggesting some selling pressure earlier in the day. However, the stock’s ability to rebound and close with a substantial gain highlights a shift in market sentiment.</p>\n<p>Intraday volatility was measured at 6.02%, underscoring the heightened price swings experienced by Unjha Formulations today. Such volatility often attracts active traders and can be indicative of underlying changes in investor perce..."
      },
      {
        "title": "Markets Rally, But Unjha Formulations Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-ltd-falls-to-52-week-low-of-rs186-amid-market-pressure-3935953",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/UnjhaFormulatio_priceRelatedfactors_3935953.png",
        "date": "2026-04-07 12:05:09",
        "description": ""
      },
      {
        "title": "Markets Rally, But Unjha Formulations Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-ltd-falls-to-52-week-low-of-rs1899-amid-market-downturn-3930348",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/UnjhaFormulatio_priceRelatedfactors_3930348.png",
        "date": "2026-04-02 10:43:07",
        "description": ""
      }
    ],
    "total": 143,
    "sid": "782664",
    "stock_news_url": "https://www.marketsmojo.com/news/unjha-formulations-782664"
  },
  "announcements": [
    {
      "caption": "Outcome Of Board Meeting - Appointment Of Company Secretary And Compliance Officer.",
      "datetime": "01-Jun-2026",
      "details": "REGULATION 6(1) AND 30(4) WITH PART A OF SCH II OF SEBI(LODR)REGULATION2015",
      "source": "BSE"
    },
    {
      "caption": "Publish Audited Financial Results For The Quarter And Year Ended As On 31/03/2026",
      "datetime": "20-May-2026",
      "details": "Regulation 33(3) of SEBI (lodr) 2015",
      "source": "BSE"
    },
    {
      "caption": "Publish Audited Financial Results For The Quarter And Year Ended As On 31/03/2026",
      "datetime": "20-May-2026",
      "details": "Regulation 33(3) of SEBI (lodr) 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Unjha Formulations Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

2026-06-02 08:28:41

Unjha Formulations Ltd has been downgraded from a Sell to a Strong Sell rating as of 1 June 2026, reflecting deteriorating technical indicators and persistent financial weaknesses. Despite a very attractive valuation, the company’s flat quarterly performance, operating losses, and bearish technical trends have compelled analysts to revise their outlook, signalling caution for investors in this pharmaceuticals micro-cap.

Read full news article

Unjha Formulations Ltd Upgraded to Sell on Technical Improvements Despite Financial Challenges

2026-05-26 08:20:17

Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 25 May 2026, driven primarily by a shift in technical indicators despite ongoing challenges in financial performance and valuation metrics. This nuanced change reflects a complex interplay of quality, valuation, financial trends, and technical signals that investors should carefully consider.

Read full news article

Are Unjha Formulations Ltd latest results good or bad?

2026-05-19 19:17:21

Unjha Formulations Ltd's Q4 FY26 results highlight a complex operational landscape characterized by significant revenue growth juxtaposed with widening losses. The company reported net sales of ₹3.28 crores for the quarter, reflecting a year-on-year increase of 38.40% from ₹2.37 crores in Q4 FY25. However, this revenue growth did not translate into profitability, as the company experienced a net loss of ₹0.74 crores, which is a deterioration from the loss of ₹0.41 crores in the same quarter last year. The quarter-on-quarter performance reveals further challenges, with a notable decline in revenue of 25.62% from ₹4.41 crores in Q3 FY26. This decline coincided with a shift from a profit of ₹0.24 crores in the previous quarter to a loss of ₹0.74 crores, raising concerns about the company's operational stability. Operating margins also reflected significant strain, with an operating margin of -13.72% in Q4 FY...

Read full news article

Unjha Formulations Q4 FY26: Losses Deepen Despite Revenue Growth as Operational Challenges Mount

2026-05-18 20:46:31

Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported a troubling quarterly performance for Q4 FY26, posting a net loss of ₹0.74 crores despite revenue growth. The micro-cap company, with a market capitalisation of ₹9.00 crores, saw its stock decline 0.55% to ₹20.00 following the results announcement, reflecting investor concerns about deteriorating profitability and operational challenges that have plagued the company throughout the fiscal year.

Read full news article

Unjha Formulations Ltd Downgraded to Strong Sell Amid Technical and Financial Weakness

2026-05-08 08:05:33

Unjha Formulations Ltd has been downgraded from a Sell to a Strong Sell rating as of 7 May 2026, reflecting deteriorating technical indicators and underwhelming financial performance. The company’s micro-cap status, combined with a sharp decline in share price and weak debt servicing ability, has prompted a reassessment of its investment appeal across quality, valuation, financial trend, and technical parameters.

Read full news article

Unjha Formulations Ltd Upgraded to Sell on Technical Improvement Despite Mixed Fundamentals

2026-04-30 08:03:55

Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 April 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The micro-cap pharmaceutical company’s Mojo Score has improved to 31.0, reflecting a nuanced change in market sentiment and technical trends, even as financial performance remains flat and long-term fundamentals show weaknesses.

Read full news article

Why is Unjha Formulations Ltd falling/rising?

2026-04-30 01:38:25

Intraday Volatility and Trading Dynamics

Despite opening the day with a gap down of 6.47%, the stock managed to recover strongly, touching an intraday high of ₹22.00. The trading range was wide, spanning ₹2.5, reflecting significant price fluctuations throughout the session. The weighted average price indicated that a larger volume of shares was traded closer to the day’s low, suggesting some selling pressure earlier in the day. However, the stock’s ability to rebound and close with a substantial gain highlights a shift in market sentiment.

Intraday volatility was measured at 6.02%, underscoring the heightened price swings experienced by Unjha Formulations today. Such volatility often attracts active traders and can be indicative of underlying changes in investor perce...

Read full news article